"All-cause mortality” or death by all causes has been shown to increase in men who have deficiencies of testosterone. A new study, conducted in Germany, recently came to this conclusion. In this study, The Study of Health in Pomerania (SHIP), the researchers looked at death rates from any cause in almost 2,000 men aged 20 [...]
Researchers from the Massachusetts General Hospital have reported at the 2008, 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego, April 12-16.1 that Fareston® (toremifene citrate) decreases the risk of new vertebral fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). As we all know from our own [...]
Posted on the Prostate Problems Mailing list about two months ago was a notice from Dr. Richard Lam about a clinical trial in which his office, Prostate Oncology Specialists, will participate. What I found particularly interesting in this trial is that it was evaluating a potential new drug, abiraterone acetate, which could be used after [...]
The use of ADT is the treatment of choice for advanced, metastatic prostate cancer as long as the cancer is responsive to the blockade. The theory goes that the suppression of circulating testosterone, which fuels prostate-cancer growth, whether by surgical castration (orchiectomy) or castration with testosterone-blocking drugs slows down the progression of the prostate cancer. [...]
CAUTION, some doctors use estrogen patches as a form of first line hormone blockade therapy for the treatment of prostate cancer. However, scientists from Weill Cornell Medical College, New York City have described the hormone estrogen as a potential key negative player in about half of all prostate cancers. Researchers have found that Estrogen-linked signaling [...]